WINDTREE THERAPEUTICS
  • COMPANY
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CONTACT US
    • DIVERSITY, INCLUSION AND INNOVATION
  • PIPELINE AND TECHNOLOGY
    • Pipeline and Therapeutic overview
    • Istaroxime
    • SERCA2a Activators
    • aPKCi inhibitors
    • Rostafuroxin
    • Expanded Access Policy
  • BUSINESS DEVELOPMENT
  • INVESTORS
    • Welcome
    • Press Releases
    • EVENTS
    • Corporate Presentation
    • Corporate Governance
    • FILINGS
      • SEC FILINGS
      • OWNERSHIP
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • FINANCIAL FUNDAMENTALS
    • FINANCIAL INFORMATION
      • IR SNAPSHOT
      • ANNUAL REPORTS
      • ANALYST COVERAGE
    • Investor Alerts
  • CONTACT US
Select Page

aPKCi inhibitors

  • OVERVIEW
  • MANAGEMENT
  • BOARD OF DIRECTORS
  • CONTACT US
  • DIVERSITY, INCLUSION AND INNOVATION
atypical protein kinase c iota aPKCi inhibitor
Oncology Asset aPKCi inhibitor topical var 101 and oral var 102
Oncology Asset aPKCi inhibitor topical and oral
Matching Preclinical Data Attributes Scientific Rationale And Market Opportunities for optimal development path
© Copyright 2022 Windtree Therapeutics, Inc.